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Methods: Between 1990 and 1995, 48 homograft valves (15 aortic and 33 
pulmonary), cryopreserved on-site, were implanted to reconstruct he right 
ventricular outflow tracts in 44 children (mean age 6.2 +- 6.0 years; range 
3 days to 20.2 years). Blinded serial echocardiographic follow-up evaluation 
was performed for all 45 valves in the 41 survivors. Results: Four homograft 
valves were replaced because of pulmonary insufficiency (3) or stenosis and 
insufficiency (1). Freedom from reoperation was 90% (70% interval, 84% to 
97%) at 50 months. During the follow-up period 15 valves developed 
progressive pulmonary insufficiency of at least two grades. Three valves 
developed transvalvular gradients of ->50 mm Hg, and one of these valves 
was also insufficient. The freedom from echocardiographic failure (two or 
more grades of pulmonary regurgitation or ->50 mm Hg gradient) was 44% 
at 50 months (70% confidence interval, 32% to 55%). Young age (p = 0.03), 
low operative weight (p = 0.04), small graft size (p = 0.04), and homograft 
retrieval-to-cryopreservation timeof less than 24 hours (p = 0.02) were 
significantly associated with failure. The type of donor valve (pulmonic or 
aortic), donor age, and blood group mismatch were not associated with 
failure, although blood group mismatch approached significance (p = 
0.05). Conclusions: Homografts function well as conduits between the 
pulmonary ventricle and pulmonary arteries if long-term valve competency 
is not crucial. However, many rapidly become insufficient. This has 
important implications for the choice of a valve if the indication for valve 
replacement is to protect a ventricle failing due to pulmonary insufficiency. 
Short periods between homograft retrieval and cryopreservation enhance 
viability and antigenicity. This may suggest an immunologic basis for the 
failure. (J Thorac Cardiovasc Surg 1996;112:1170-9) 
H omograft valves are widely used in the repair of 
congenital heart anomalies as conduits between 
the pulmonary ventricle and pulmonary arteries and 
as valves to protect a ventricle failing due to pulmo- 
nary insufficiency and stenosis. The freedom from 
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reoperation rates reported for series of cryopre- 
served valves for right ventricular outflow tract 
(RVOT) reconstruction in the young have been 
55% to 80% at 4 to 6 years. 1-4 Doubt has been 
expressed about the durability of homografts in in 
the aortic and pulmonary positions in children. 5-7 
Adequate homograft function is usually reported 
in terms of freedom from reoperation, but this is a 
relatively insensitive measure of valve integrity. Pul- 
monary insufficiency may be well tolerated if the 
pulmonary arteries are normal and pulmonary resis- 
tance is low. However, many children requiring 
RVOT reconstruction have abnormal pulmonary 
vasculature and decreased right ventricular func- 
tion. Longer follow-up demonstrates that a compe- 
tent, nonstenotic pulmonary valve is important o 
preserve ventricular function and optimize exercise 
capacity, a-l° 
This study was undertaken to examine the inci- 
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Table I. Homograft valve patients 
Primary diagnosis No. 
Pulmor/ary atresia or ventricular septal defect 13 
Tetralogy of Fallot 8 
Complex transposition 8 
Truncus arteriosus 5 
Double outlet right ventricle 4 
Pulmonary stenosis/atresia 3 
Aortic stenosis (Ross procedure) 3 
Total 44 
dence, progression, and determinants of cryopreserved 
homograft valve failure in the RVOTs of children. 
Methods 
Patient population. From December 1990 to May 1995 
at the IWK Children's Hospital 48 cryopreserved ho- 
mograft valves (33 pulmonary and 15 aortic) were im- 
planted in 44 patients (22 girls and 22 boys) for recon- 
struction of the RVOT or pulmonary valve replacement 
for a variety of congenital lesions (Table I). The mean age 
at operation was 6.2 ± 6.0 years (range 3 days to 20.2 
years), and 15 patients were younger than 1 year. Mean 
weight was 21.0 _+ 18.3 kg (range 2.8 to 72 kg). Forty-one 
(85%) of 48 patients had undergone at least one previous 
cardiac operation (Table II). 
Homograft procurement and preparation. The 48 ho- 
mograft valves were harvested en bloc with the heart by a 
surgeon or a tissue bank technologist under sterile condi- 
tions from 39 donors; both valves were used from nine 
donors (Table III). 
Donors as old as 65 years were accepted. Standard 
exclusion criteria included historic or serologic evidence 
of viral infection (e.g., human immunodeficiency virus, 
hepatitis B or C), malignancy (except nonmetastatic cen- 
tral nervous system tumors), long-term eorticosteroid 
therapy, or evidence of valvular heart disease or cardiac 
trauma. The valves were incubated in 500 ml of Hanks 
balanced salt solution containing 40 mg of gentamicin and 
500 mg of cefazolin at 4 ° C for a mean of 31.3 - 11.5 
hours (range 12 to 72 hours). Valves were then inspected, 
trimmed, and measured, and macroscopically defective 
valves were discarded. Four small tissue biopsy specimens 
were obtained from each valve for culture of aerobic 
bacteria, anaerobic bacteria, fungi, and mycobacteria. The 
valves were then cryopreserved in Hanks balanced salt 
solution with 10% dimethylsulfoxide as a cryoprotectant. 
The valves were cooled in a controlled-rate freezer 
(Planer KRYO10, Planer Products Ltd., Sunbury-on- 
Thames, Middlesex, U.K.) at 1 ° C/minute to a tempera- 
ture of -80 ° C and stored in vapor-phase liquid nitrogen 
below -135° C until used. Valves were transported in a 
cooler with liquid nitrogen to the operating theater and 
thawed in a water bath at 39 ° C. 
Operative technique. All valves were implanted by two 
surgeons. The operations were performed through a 
median sternotomy with standard cardiopulmonary tech- 
niques and mild hypothermia (32 ° C). The aortic root was 
Table II. Previous cardiac surgery 
Procedure No. 
Modified Blalock-Taussig shunt 22 
Tetralogy of Fallot repair 13 
Pulmonary valve replacement 8 
Central shunt 6 
Aortic valvotomy 6 
Rastelli repair 5 
Arterial switch 4 
RVOT annular patch 4 
Pulmonary valvotomy 3 
VSD repair 2 
Senning 1 
RVOT, Right ventricular outflow tract; VSD, ventricular septal defects. 
*Three valvotomies were performed in one patient and two in another one. 
Table I I I. Homografi valve characteristics 
Source No. Mean Range 
Heart transplant 4 
recipients 
Brain-dead multiorgan 11 
donors 
Tissue-only donors 24 
Total* 48 
Age of donor 
Valve size 
Ischemic time? 
Retrieval-to-preservation 
time~ 
20.3-+ 16.8yr 3 days to 58 yr 
17.2-+3.7mm 9to25mm 
4.4 _+ 3.7 hr 1 to 18.5 hr 
31.3±11.5hr 12to72hr 
*Both valves were used from nine donors. 
?Time from heart cessation tovalve incubation at 4 ° C in Hanks balanced 
salt solution and antibiotics. 
~Time from onset of valve incubation to onset of cryopreservation. 
not routinely crossclamped unless other procedures, uch 
as ventricular septal defect closure or an aortic autograft 
procedure, were required. In seven patients the pulmo- 
nary reconstruction involved implanting the homograft as 
a bifurcated graft; the others had circumferential distal 
anastomosis. Proximal extensions of autologous pericar- 
dium or homograft material were added in 22 patients. An 
additional four patients had proximal extensions of Da- 
cron polyester fiber. All proximal extensions were placed 
as patches and none as tubular grafts. Valve size was 
determined by the surgeon and was always larger than the 
minimum acceptable pulmonary annulus diameter as de- 
termined by Pacifico and colleagues. 11Pulmonary valves 
were used preferentially. No attempt was made to match 
donor and recipient for blood type. 
Eehocardiographic evaluation. All surviving patients 
were examined in the immediate postoperative p riod and 
reexamined serially with transthoracic echocardiograms 
every 6 to 12 months. All studies were reviewed in a 
random and blinded fashion by one pediatric ardiologist. 
Pulmonary regurgitation (PR) was assessed by looking at 
1172 Baskett et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
November 1996 
] 
_z o.8 
0.6 
(/1 
Z 
O 
m 
0.4 
O 
n 
O 
0.2 
t~ 
'I 
N:44 23 18 11 7 1 
[ I I I 
0 10 2o 30 40 50 
MONTHS 
Fig. 1. Actuarial survival of all patients undergoing reconstruction of the right ventricular outflow tract 
with a cryopreserved homograft. 
the regurgitant jet with pulsed color-flow Doppler, partic- 
ularly its width at the source and how far it entered the 
corresponding ventricle. The severity was graded semi- 
quantitatively from 0 to 4+, in a manner similar to that 
described by Chan and coworkers6: 0, absent; 1+, a 
pinhole jet; 2+, a jet of regurgitation approximately 20% 
of the valve annulus; 3+, a wide-based jet approximately 
40% of the annular width; 4+, a broad jet larger than 40% 
of the annular width. When possible, observations were 
made with the short-axis parasternal view. Stenosis was 
assessed by measuring the peak velocity through the valve 
with continuous-wave Doppler technique. The highest 
peak velocity was used in the simplified Bernoulli equa- 
tion: gradient = 4 × peak velocity 2. 
Statistical analysis. Data are presented as the mean _+ 
the standard eviation. All statistical tests were conducted 
with SAS version 6.08 (SAS Institute Inc., Cary, N.C.). 12 
Twelve variables were analyzed in a univariate analysis for 
significant association with echocardiographic failure. 
Continuous variables were analyzed with Student's t test 
and categorical variables using a X a test. A forward 
stepwise discriminant function analysis was also con- 
ducted to determine which combination of these variables 
best predicted valve failure. Variables were chosen to 
enter the model based on a critical F test (p < 0.05) from 
an analysis of covariance in which the variables already 
added to the model act as covariates and the variable 
under consideration is the dependant variable. 12 The 
outcome measure of valve failure was defined as a pro- 
gression of ->2+ PR or a transvalvar gradient of >-50 mm 
Hg. Because of the inherent subjectivity in interpreting 
echocardiograms, a change of >-2+ PR or a >-50 mm Hg 
gradient was thought o be significant and is supported in 
the literature. 6 
Life tables for freedom from valve failure, reoperation, 
or death were calculated using the Blossom statistical 
program (Blossom, BR Cole, National Institutes of 
Health, Bethesda, Md.). Confidence intervals (70%) were 
approximated from the standard error for actuarial sur- 
vival estimates. 
Results 
The three early deaths all were patients with 
complex truncus arteriosus, and there were no late 
deaths. No patient was lost to follow-up. Actuarial 
survival was 93% at 50 months (70% confidence 
interval, 89% to 97%) (Fig. 1). 
Four valves (8.9%), have been explanted, result- 
ing in an actuarial f reedom from reoperation rate of 
90% at 50 months (70% confidence interval, 84% to 
97%) (Fig. 2). The first homograft  was removed 14 
months after implantation in an l l -year-old patient 
with complex tetralogy of Fallot. The valve had 
become acutely insufficient because of embolization 
of a clam shell device that had been used to close a 
ventricular septal defect 5 months  earlier. At reop- 
eration the device was found in the main pulmonary 
artery. The leaflets of the valve were found to be in 
good condition, except for a tear. The most recent 
echocardiogram had shown no regurgitation and no 
gradient. The new homograft functioned well for 3 
months but showed a progressive increase of PR  to 
4+ at 22 months after implantation. 
The second pulmonary valve reoperation was in a 
7-month-old child 5 months after implantation. This 
patient with tetralogy of Fallot and pulmonary atre- 
sia developed an RVOT aneurysm, pulmonary re- 
gurgitation, and right ventricular failure. At reop- 
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Fig. 2. Actuarial freedom from reoperation i the 41 survivors. 
eration there was no evidence of the valve tissue. 
The replacement homograft was functioning well, 
with trivial regurgitation a d a moderate gradient of 
40 mm Hg seen at the last echocardiogram 2 years 
later. 
A third child, also with tetralogy of Fallot and 
pulmonary atresia, had a homograft implanted when 
he was 2 years 9 months old because of continued 
right ventricular failure after tetralogy repair. This 
child developed 2+ PR within 5 months of the 
operation. He remained well clinically, but the re- 
gurgitation continued to increase and was 4+ 2 
years after the operation. The homograft also be- 
came progressively obstructive; the initial gradient 
was 24 mm Hg, and it had progressed to 90 mm Hg 
at the time of reoperation. At reoperation 4 years 
after implantation, the leaflets were still present but 
furled together. Immediately after the operation the 
replacement homograft had a 1+ PR grade and a 
transvalvular g adient of <20 mm Hg. Four months 
later there is no change on echocardiography, and 
the child is without symptoms. 
The fourth child also suffered from tetralogy of 
Fallot with pulmonary atresia. The first homograft 
was inserted in the ll-month-old child because of 
congestive failure due to high pulmonary artery 
pressures. The valve developed 2+ PR within 2 
months, and 7 months after it was implanted, the 
homograft was replaced because of worsening con- 
gestive failure. The new homograft also rapidly 
developed 2+ PR. The patient's condition is stable, 
but the patient has limited exercise tolerance and 
remains in right-sided heart failure. 
Postoperative echocardiograms were obtained in 
all 45 valves in the 41 survivors at a mean of 9.8 _+ 
9.5 days (range 1 to 41 days) after repair. The mean 
follow-up time was 20.6 _+ 15.8 months (range 3 to 
52 months). For four patients the echocardiographic 
windows were inadequate to allow comment on 
valve function; the echocardiographic foll0w-up is 
therefore for 41 (91%) of 45 valves. Three of the 
patients had initial postoperative echocardiograms 
showing 2+ or 3+ PR and were excluded from the 
statistical analysis because they were considered 
technical failures. Figure 3 shows the extent of 
pulmonary regurgitation atthe last echocardiogram. 
Only three valves had a gradient of ->50 mm Hg, 
(Fig. 4) one of these also had 4+ PR. The other two 
had no PR. 
Seventeen (45%) of 38 of the valves failed (15 
with ->2+ PR grades, two with ->50 mm Hg gradi- 
ents, and one with both). Actuarial freedom from 
failure was 44% at 26 and 50 months (70% confi- 
dence interval, 32% to 55%) (Fig. 5). The mean 
time to failure was 8.9 -+ 6.9 months (range 1 to 26 
months). 
The univariate analysis howed that young age at 
operation, low weight, small graft size, and a time 
for homograft retrieval to cryopreservation f less 
than 24 hours were significantly associated with the 
development of ->2+ PR or a ->50 mm Hg trans- 
valvular gradient. None of the other variables was 
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found to be statistically significantly associated with 
failure, although blood group mismatch approached 
significance (Table IV). The multivariate analysis 
showed that retrieval-to-cryopreservation time of 
less than 24 hours, blood group mismatch, and small 
valve size together predicted 84% of the failures. 
The partial correlation coefficients for each of these 
variables were approximately equal (Table V). 
These three variables are equally important predic- 
tors of failure. Weight and age at operation, signif- 
icant in the univariate analysis, were not significant 
predictors of failure in the stepwise discriminant 
function analysis. They were associated with valve 
size, and when valve size was controlled for in the 
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gradient) for the 38 valves analyzed. 
multivariate analysis, age and weight became insig- 
nificant. 
Discussion 
All the patients requiring reoperation had tetral- 
ogy of Fallot with significant distal pulmonary artery 
stenosis. In each case when the valve became incom- 
petent and ceased to protect the ventricle, heart 
failure developed, leading to reoperation. It is these 
patients in whom the homograft is most needed as a 
competent valve rather than a mere conduit. Long- 
standing PR is associated with decreased exercise 
tolerance and right ventricular dysfunction after 
repair of tetralogyfi' 9 Pulmonary insufficiency after 
RVOT reconstruction is no longer thought o be 
innocuous. 13 The low reoperation rate (see Fig. 2) is 
in keeping with that reported in other series, but it 
masks the true incidence of valve failure. 1' 14 
Although somewhat subjective, echocardiography 
provides a more sensitive measure of valve function 
than freedom from reoperation rates. Echocardiog- 
raphy has been shown to be a reliable method of 
assessing homograft function. 6'a5 
Several factors have been associated with ho- 
mograft failure when reoperation was used as the 
outcome measure: young age, 1'5-7 small valve 
size,a, 7 and the use of aortic valves in the RVOT in 
some series; 2'7 but not in others. 1'6 Our results 
confirm young age and small graft size but not valve 
type. However, on the basis of the results reported 
by others, we preferentially used pulmonary valves 
when possible)' 7 How the various factors in valve 
preparation affect valve longevity has not been fully 
determined. 
It has been suggested that homograft valve failure 
may result from immunologic rejection, which may be 
heightened in young children, 5'7,16 and immunosup- 
pression has been suggested by some research. 5' 17, is 
Much of the work with cryopreservation has empha- 
sized the maintenance ofviability, based on the belief 
that the durability of homograft valves is related to the 
viability of fibroblasts, which maintain the valve ma- 
trix.19, 20 Homograft valve viability is determined by 
the time between donor heart cessation and harvest 
and by the preservation technique. 19' 21 Cryopreserved 
valves are thought o retain viability, but they also 
retain their immunogenicity, s' 22-24 Viability and im- 
munogenicity decline as the duration of wet storage at 
4°C increases. 24-26 The length of time the valve is 
sterilized before freezing (i.e., retrieval-to-preservation 
time) is thought o be an important determinant of 
immunogenicity. There may be a trade-off between 
retained structural integrity and retained immunoge- 
nicity, both of which are preserved by cryopreserva- 
tion. 
Viable endothelial cells are thought o provide 
the strongest antigenicity. 24' 27, 28 Endothelial cells 
are the most susceptible to ischemic damage and, 
when stored in antibiotic solution, are nonviable 
after 24 hours to 14 days, depending on the type of 
donor and the length of  ischemic time before pro- 
cessing.Y, 25,27 Lang and associates demonstrated 
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Table IV. Results of statistical analysis 
Variables p Value* Test used 
Continuous 
Young age at operation 0.03 
Low weight at operation 0.04 
Small graft size 0.04 
Donor age 0.32 
Valve ischemic time? 0.76 
Categorical 
Retrieval to preservation time 0.02 X 2 
<24 or >24 hr$ 
Graft type (pulmonic or aortic) 0.58 
Graft or host size mismatch§ 0.58 )(2 
Blood g.roup mismatch 0.05 X 2 
Previous cardiac surgery 0.88 )(2 
Donor type (organ or tissue) 0.44 X a 
Use of Dacron 0.68 
Student test 
Student test 
Student test 
Student test 
Student test 
*Rounded off to two decimal places. 
fTime from heart cessation to valve incubation at 4 ° C in antibiotic and 
Hank's balanced salt solution. 
:~Time from onset of valve incubation to onset of cryopreservation. 
§Valve size >95th percentile for the patient's weight as described by 
Pacifico, Kirklin, and Blackstone. I1 
that, after 12 to 24 hours of storage at 4 ° C before 
cryopreservation, endothelial cells of the ho- 
mografts retained the capacity to proliferate, but 
those stored for 3 weeks at 4 ° C did not. 29 Although 
homograft immunogenicity has been demonstrated 
to be retained espite the attenuation of endothelial 
viability, 24 it is apparent that the precise nature of 
homograft valve viability and immunogenicity is not 
understood. 
Five valves in our series had retrieval-to-preser- 
vation times of less than 24 hours. Four of the 17 
valves that failed had retrieval-to-preservation mes 
of less than 24 hours, and none of the competent 
valves had a time less than 24 hours. The fifth valve 
had an initial postoperative echocardiogram show- 
ing a 2+ insufficiency and was thus excluded from 
the analysis, although at the most recent echocar- 
diogram it was judged to have 3+ insufficiency. 
Valves with short retrieval-to-preservation times 
(<24 hours) were significantly more likely to fail 
(p = 0.02). 
Blood group incompatibility approached signifi- 
cance in the current Series (p = 0.05) and was a 
significant predictor of failure in the multivariate 
analysis (see Table V). The significance of biood 
group incompatibility has long been postulated and 
its importance suggested by some, 3° although other 
studies have failed to demonstrate this. TM 32 HOW- 
ever, ABO matching has often been carried out to 
Table V. Results of stepwise discriminant function 
analysis 
Variable* Partial r a F statistic p Value 
Retrieval to preservation time 0.145 6.121 0.018 
<24 hours 
Graft size 0.143 5.857 0.020 
Blood group mismatch 0.157 6.36i 0.017 
*These three variables together predicted 84% of the failures, 
some extent, 5'7' 27, 33 and it is recommended by 
several investigators. 24'27 Homograft ischemic time 
was not shown to be a significant factor in valve 
failure in our series (p = 0.76), although the isch- 
emic times were all quite short and relatively con- 
sistent (Table IV). 
Results from earlier work with stored antibiotic- 
sterilized valves (i.e., fresh valves) appear to be at 
least as good and perhaps better than those 
achieved with the cryopreserved valves, particularly 
considering the longer follow-up. 33-36 This may be 
the result of decreased antigenicity, which has been 
demonstrated in homografts stored for several 
weeks.24, 27 However, the great variability in patient 
selection, age, surgical technique, perioperative 
mortality, procurement and preservation tech- 
niques, and follow-up make a valid comparison 
impossible. 37 Our experience and that of others with 
cryopreserved homograft degeneration in young 
children has emphasized the need to further inves- 
tigate the cause and mechanism of this early fail- 
ure.5, 6, 16 
Factors other than rejection and growth must be 
considered in assessing the mechanisms of ho- 
mograft valve failure. 14 Geometric distortion has 
been recognized as a factor in aortic homograft 
replacement and is largely responsible for the switch 
from a subcoronary insertion to root replacement. 
This may be a factor in the pulmonary position as 
well. However, all the valves in our study were 
implanted as intact cylinders. Christie and Barratt- 
Boyes demonstrated that the loss of valve leaflet 
extensibility over time leads to increasing Valve 
incompetence.38 This could explain long-term fail- 
ure, and the effect may result from decreased via- 
bility, immunologic rejection, or a combination of 
the two in conjunction with subtle geometric distor- 
tion. Although immunologic factors do not fully 
explain valve failure, they cannot be ignored as a 
factor in early homograft valve failure, Particularly 
in young children. 
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Conclusions 
The cryopreserved homograft  is effective as a 
conduit  between the pulmonary ventricle and the 
pulmonary arteries. However,  the early develop- 
ment  of significant incompetence limits its useful- 
ness for protect ing the ventricle from high pulmo- 
nary artery pressures when a competent  valve is 
essential. Dysfunction of  the valves is common and 
progressive over the first 6 to 12 months (see Fig. 5). 
This early fai lure is more in keeping with rejection 
than the inevitible tissue degenerat ion seen in late 
failure. 38 Small graft size was a significant factor in 
valve failure, but a valve larger than the 95th 
percenti le for weight was not. 11 The practice of 
oversizing valves to allow for growth appears to be 
justified. 38 We found no difference in aort ic versus 
pu lmonary valves (p = 0.58), although pulmonary 
valves were used whenever possible; 33 pulmonary 
and 15 aort ic valves were used. 
Our  finding of short retr ieval - to-preservat ion me 
and b lood group incompatibi l i ty as significantly as- 
sociated with homograft  valve fai lure lends some 
clinical support  to the suggested immunologic  na- 
ture of early homograft  fai lure in children. A l though 
some surgeons have used a variety of immunosup-  
pressive regimens on small numbers of patients, the 
current state of knowledge does not seem to support  
this as a rout ine practice. 16' 32, 39 
Cont inued work is required to assess the signifi- 
cance of the immune response to cryopreserved 
homograft  valves. Some studies have shown an 
immune response to valves in the laboratory. 22-24 
The nature of  this response needs to be character-  
ized and methods to modify it should be assessed, 
initially in the laboratory and then clinically. Be- 
cause of the small number  of pat ients operated on at 
any single institution and the great variabi l ity in such 
a heterogenous group of patients, mult icentered 
randomized studies will be necessary to assess the 
efficacy of any clinical intervention. Interventions 
a imed at modifying the immunogenic i ty of the do- 
nor valve and the recipients response appear  to be 
indicated. 
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Discussion 
Dr. Richard A. Hopkins (Washington, D.C.). I thank the 
Association for the opportunity to comment on this paper 
and the authors for providing me a copy of the manuscript 
before this meeting. I think this is an extremely important 
paper. I agree with the authors' premise for doing the 
study, and I agree with their conclusions. I think it is a very 
important biologic and clinical experiment, which sheds 
tremendous light on the biology of cryopreserved ho- 
mografts. 
I and my colleagues have had experience with about 200 
homograft implants; the last 100 have been monitored, as 
your implants were, with every-6-month echo studies. Our 
results parallel your findings in terms of survival. How- 
ever, we have only had two patients who required replace- 
ment for homograft failure in the right-sided position and 
only three others who developed increasing right ventric- 
ular pressures or high-grade insufficiency which ultimately 
required replacement. We had little difficulty with pro- 
gressive or late regurgitation in the right ventricular 
outflow tract position. We had a freedom from structural 
failure rate of about 91%, as opposed to your 44%. Our 
replacement valves were assessed at 5.5 years, or 2000 
days, and your valves were evaluated at about 1500 days. 
I think it could be illuminating to understand the differ- 
ences in these two series, because the comparison could 
give us a clue about what to avoid in the future. 
Your results confirm that young age and small graft size 
are risk factors, and we agree with this but not with 
whether the aortic or pulmonary valve is used. It is 
interesting that your failures seem to be in other than the 
truncus series, which means that the neonates do not seem 
to be a problem in your series. We agree with that finding, 
but it is at variance with other studies, and I would like you 
to comment on the neonatal issue. 
Your finding that short retrieval-to-preservation times 
correlated with failure is the central and most important 
finding of your study. It supports our own contention that 
cryopreservation should be good but not too good. Your 
cold ischemic time after harvest but before the start of 
incubation in Hanks solution may be the key to this study. 
What fluid did you place these homografts in for the 4 ° C 
storage time? In other institutions where the processing is 
done off-site, storage is most often done in lactated 
Ringer's solution, which is our preference, because it 
effectively kills the endothelium. 
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We think the geometric factors are important ones and 
that the reconstruction must be performed to reduce 
hydraulic turbulence. We agree with your conclusion that 
oversizing isgood as long as it does not lead to distortion. 
However, the proximal reconstruction is very important. 
Did you use polytetrafluoroethylene (PTFE)* hoods to 
smooth the fluid flow entry architecture into the conduit 
to optimize hydraulics and avoid turbulence just below the 
valve leaflets? Did you avoid distal Dacron graft exten- 
sions? 
Were you able to examine your explanted valve leaflets 
for the presence of inflammatory cells, macrophages, 
fibrous sheathing, and most importantly, to look for 
preservation of donor matrix or endothelial cells? Have 
you been able to compare those with your homografts 
after the preservation techniques and before implantation 
as a comparison of the cell biology at the time of 
implantation? 
I think this is a superb and critically important study. I
applaud the authors for accomplishing it and the Associ- 
ation for selecting it for presentation. I greatly appreciate 
the opportunity to have discussed its contents. 
Dr. Baskett. Thank you very much, Dr. Hopkins. Re- 
garding the neonatal issue, we did not look specifically at 
the diagnosis; we looked at age as a continuous variable. 
Because it is quite a heterogeneous group and there are 
only 44 patients, we did not elect to look at the specific 
diagnosis because we we would not have the statistical 
power to say anything about that subject. 
With regard to the ischemic times, I welcome your 
comment that part of the problem may be that our valves 
are preserved too well with these very short ischemic 
times. When the valves are explanted, they are placed in 
Hanks balanced salt solution and then taken to the tissue 
bank, where they are stored at 4 ° C in Hanks balanced salt 
solution with the antibiotics that I listed. 
We did not use PTFE in the reconstruction of the 
outflow tract. In most cases we used proximal extensions 
of autologous pericardium. In four of the older patients 
Dacron was used. Two of the valves with Dacron failed, 
and two of them did not, which was not a significant 
finding. 
With regard to the explanted valves, the four valves that 
were removed were taken out 6 months to 2 years later. By 
the time they were removed, they were completely acel- 
lular. A pathologist reviewed the H&E stained slides of 
these valves and said there was nothing left to look at. 
Unfortunately, with a retrospective study you are not able 
to look at the explants. 
However, we have established a rat model in our 
transplantation laboratory to look at what immunologic 
factors may be involved in the failure of the homografts. 
Perhaps if I could just show another slide? 
*Gore-Tex hoods, registered trademark of W. L. Gore & Asso- 
ciates, Inc., Newark, Del. 
(Slide) This is a section taken from an explanted valve 
that was implanted in the abdominal orta of a rat. This is 
a syngenic graft at 8 weeks after implantation; and as you 
can see, there is some intimal thickening, but the valve 
leaflet itself looks quite normal. 
(Slide) This slide is taken from a partially outbred rat 
and is partially allogeneic. At 4 weeks after implantation 
the valve leaflets are quite edematous and filled with a 
mononuclear type infiltrate. 
These are some of the preliminary things that we are 
working on to qualify the immune response. 
Dr. Patrick G. Hogan (Brisbane, Queensland, Australia). 
We are also interested in laboratory aspects of the 
immune response in a rat model and in human studies. 
The big problem is establishing the link between the 
data we have available for humans and whether the 
valve is actually damaged. Have you seen, given that 
you have got retrospective echocardiographic data, any 
suggestion of nodularity or thickening of the valve? If 
not, do you think that is something that could be looked 
for in the future? 
Dr. Baskett. Thank you, Dr. Hogan. In the early 
echocardiograms that we reviewed (we had an initial 
postoperative one for each patient, usually within a week 
of his or her operation), the valves, except those we 
excluded, looked very good. As we monitored them, we 
could see an increase of insufficiency or transvalvular 
gradient, but we could not see any leaflet abnormalities at 
all. It is a very good point. Thank you. 
Dr. Flavian M. Lupinetti (Seattle, Wash.). I would like 
to clarify some of our previous work that showed that 
various neglectful methods of preservation could reduce 
but not abolish immunogenicity. It seems that the valve 
can run but it cannot hide. I notice that in your analysis 
three of the four factors related with failure--young age, 
small size, and small graft--were perhaps really the same 
factor, and perhaps an analysis of covariance would have 
shown that only one of those was truly related to valve 
failure. 
I wonder if there was also a difference in the duration of 
ischemia in the smaller valve such that an analysis of 
covariance or a multivariate analysis may have eliminated 
the ischemic time as a factor leading to valve degenera- 
tion? 
Dr. Baskett. Thank you, Dr. Lupinetti. We did perform 
a multivariate analysis, and with your permission, I will 
show it. We performed a forward stepwise discriminate 
function analysis for the variables I listed. As Dr. Lupin- 
etti mentioned, the age, graft size, and weight of the 
patient are related. When you run these factors in a 
multivariate analysis, graft size comes out as the most 
significant of the three; when you control for it, the other 
two drop out. The three variables--retrieval-to-preserva- 
tion time less than 24 hours, small graft size, and blood 
type mismatch--were all significant in the multivariate 
analysis. Ischemic time was not. 
